Precipio Inc (PRPO) - Total Liabilities
Based on the latest financial reports, Precipio Inc (PRPO) has total liabilities worth $7.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PRPO financial resilience to evaluate the company's liquid asset resilience ratio.
Precipio Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Precipio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PRPO asset base.
Precipio Inc Competitors by Total Liabilities
The table below lists competitors of Precipio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ilshinstone
KO:007110
|
Korea | ₩33.23 Billion |
|
Goldspot Discoveries Corp
V:SPOT
|
Canada | CA$11.69 Million |
|
Metrod Holdings Bhd
KLSE:6149
|
Malaysia | RM1.57 Billion |
|
US Global Investors Inc
NASDAQ:GROW
|
USA | $2.87 Million |
|
Ludan Engineering Co. Ltd
TA:LUDN
|
Israel | ILA188.66 Million |
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
Korea | ₩39.86 Billion |
|
Pantaflix AG
XETRA:PAL
|
Germany | €52.66 Million |
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
Thailand | ฿1.88 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Precipio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Precipio Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precipio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precipio Inc (1999–2024)
The table below shows the annual total liabilities of Precipio Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.90 Million | +33.50% |
| 2023-12-31 | $3.67 Million | -28.52% |
| 2022-12-31 | $5.14 Million | -11.96% |
| 2021-12-31 | $5.83 Million | -10.93% |
| 2020-12-31 | $6.55 Million | +3.89% |
| 2019-12-31 | $6.31 Million | -59.27% |
| 2018-12-31 | $15.48 Million | +8.76% |
| 2017-12-31 | $14.23 Million | -30.93% |
| 2016-12-31 | $20.61 Million | +16.86% |
| 2015-12-31 | $17.64 Million | -24.80% |
| 2014-12-31 | $23.45 Million | +24.54% |
| 2013-12-31 | $18.83 Million | +1.70% |
| 2012-12-31 | $18.52 Million | -17.75% |
| 2011-12-31 | $22.51 Million | -4.31% |
| 2010-12-31 | $23.53 Million | +441.85% |
| 2009-12-31 | $4.34 Million | -0.21% |
| 2008-12-31 | $4.35 Million | -12.77% |
| 2007-12-31 | $4.99 Million | -6.40% |
| 2006-12-31 | $5.33 Million | -28.32% |
| 2005-12-31 | $7.43 Million | -64.47% |
| 2004-12-31 | $20.92 Million | +70.83% |
| 2003-12-31 | $12.25 Million | -2.18% |
| 2002-12-31 | $12.52 Million | +74.34% |
| 2001-12-31 | $7.18 Million | +84.30% |
| 2000-12-31 | $3.90 Million | -82.34% |
| 1999-12-31 | $22.06 Million | -- |
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more